Patents by Inventor Omar Duramad

Omar Duramad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO TIGIT
    Publication number: 20240115696
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: June 21, 2023
    Publication date: April 11, 2024
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • Antibodies to TIGIT
    Patent number: 11723971
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 15, 2023
    Assignees: JN Biosciences, LLC, Abmuno Therapeutics, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES
    Publication number: 20220363774
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: November 17, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES
    Publication number: 20220185906
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES
    Publication number: 20220185907
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • METHODS OF USE OF ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES
    Publication number: 20220185908
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Composite binding molecules targeting immunosuppressive B cells
    Patent number: 11299551
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: April 12, 2022
    Assignee: Biograph 55, Inc.
    Inventors: Leonard Presta, Paul Tumeh, Nils Lonberg, Omar Duramad
  • COMPOSITE BINDING MOLECULES TARGETING IMMUNOSUPPRESSIVE B CELLS
    Publication number: 20210269545
    Abstract: Targeting immunosuppressive B-cell populations with bispecific or multivalent targeting molecules presents a potential pathway for therapeutic intervention that effectively modulates the anti-tumor immune response to improve therapeutic outcomes. Accordingly, there remains a need for engineered antibody-based therapeutics that can effectively and selectively target immunosuppressive B-cell populations for the treatment of cancer. Provided are composite binding molecules that target immunosuppressive B cells.
    Type: Application
    Filed: April 13, 2021
    Publication date: September 2, 2021
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • CD20 BINDING MOLECULES AND USES THEREOF
    Publication number: 20210032357
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 4, 2021
    Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • Multimeric bispecific binding molecules specific for CD20 and CD3
    Patent number: 10787520
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 29, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • Antibodies to TIGIT
    Publication number: 20200297844
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: December 4, 2019
    Publication date: September 24, 2020
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • Antibodies to TIGIT
    Patent number: 10537633
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 21, 2020
    Assignees: JN Biosciences LLC, Abmuno Therapeutics LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • CD20 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190100597
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Application
    Filed: March 4, 2015
    Publication date: April 4, 2019
    Applicant: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • Preparation for preventing or treating type I diabetes
    Patent number: 9821035
    Abstract: The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) ?-GalCer.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: November 21, 2017
    Assignee: REGIMMUNE CORPORATION
    Inventors: Omar Duramad, Hidetoshi Akimoto, Yasuyuki Ishii, Haruhiko Morita
  • ANTIBODIES TO TIGIT
    Publication number: 20170281764
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: March 3, 2017
    Publication date: October 5, 2017
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • PREPARATION FOR PREVENTING OR TREATING TYPE I DIABETES
    Publication number: 20150238572
    Abstract: The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) ?-GalCer.
    Type: Application
    Filed: August 22, 2013
    Publication date: August 27, 2015
    Applicant: REGIMMUNE CORPORATION
    Inventors: Omar Duramad, Hidetoshi Akimoto, Yasuyuki Ishii, Haruhiko Morita